Daniel J Capon

6406697, Jun 18, 2002

Aug 5, 1997

08/906549

Daniel J. Capon - San Mateo CA
Laurence A. Lasky - Sausalito CA

Genentech, Inc. - South San Francisco CA

C07K 1646

4241781, 435 697, 514 2, 530350, 536 234

Novel polypeptides are provided, together with methods for making and using them, and nucleic acids encoding them. These polypeptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.

6407221, Jun 18, 2002

Jun 7, 1995

08/475442

Daniel J. Capon - Hillsborough CA
Arthur Weiss - Mill Valley CA
Brian A. Irving - San Francisco CA
Margo R. Roberts - San Francisco CA
Krisztina Zsebo - Woodside CA

Cell Genesys, Inc. - Foster City CA
Regents of the University of California - Oakland CA

C07H 2104

536 234, 435 691, 435 697, 4353201, 435325, 435 6, 4352351, 530300, 530350, 536 231, 536 2353, 536 2352

Chimeric proteins and DNA encoding chimeric proteins are provided, where the chimeric proteins are characterized by an extracellular domain capable of binding to a ligand in a non-MHC restricted manner, a transmembrane domain and a cytoplasmic domain capable of activating a signaling pathway. The extracellular domain and cytoplasmic domain are not naturally found together. Binding of ligand to the extracellular domain results in transduction of a signal and activation of a signaling pathway in the cell, whereby the cell may be induced to carry out various functions relating to the signalling pathway. A wide variety of extracellular domains may be employed as receptors, where such domains may be naturally occurring or synthetic. The chimeric DNA may be used to modify lymphocytes as well as hematopoietic stem cells as precursors to a number of important cell types.

6432677, Aug 13, 2002

Sep 21, 1992

07/949327

Daniel J. Capon - San Mateo CA
David V. Goeddel - Hillsborough CA

Genentech, Inc. - South San Francisco CA

C12P 2104

435 6951, 4353201, 435325, 435 691, 4352523, 4352528, 530351, 530324, 536 2352

Distinct -, - and -interferon genes from various animal species have been identified, cloned and expressed to produce the corresponding non-human animal interferon proteins. Specifically disclosed are interferons of bovine, porcine, feline and rabbit origin.

6514752, Feb 4, 2003

May 18, 1995

08/443613

Raju Kucherlapati - Darien CT
Beverly H. Koller - Carrboro NC
Oliver Smithies - Chapel Hill NC
Robert B. Dubridge - Belmont CA
Gary Greenburg - San Carlos CA
Daniel J. Capon - Hillsborough CA
Steven R. Williams - San Francisco CA
Mariona Lourdes Arbones De Rafael - Barcelona, ES

Cell Genesys, Inc. - Foster City CA

C12N 1574

4353201, 435325, 435455, 536 231, 800 13

Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the -microglobulin gene is inactivated for reducing or eliminating the expression of functional Class I MHC antigens. The resulting cells may be used as universal donor cells. In addition, embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts, which may be used as source of universal donor organs, or as models for drug and transplantation therapies. Methods for homologous recombination in non-transformed mammalian somatic cells are also described.

6534285, Mar 18, 2003

Apr 12, 2000

09/547692

Phillip W. Berman - Burlingame CA
Daniel J. Capon - San Mateo CA
Laurence A. Lasky - San Francisco CA

Genentech, Inc. - South San Francisco CA

C12P 2106

435 691, 4241841, 4242041, 4242081, 530350, 536 231

Diagnostic product and vaccine for Acquired Immuno-deficiency Syndrome (AIDS) and methods for making and using same, wherein viral polypeptide sequences from an AIDS associated retrovirus are expressed directly or as a fusion polypeptide in a prokaryotic or mammalian cell expression host to produce a diagnostic product which specifically binds complementary antibody produced by individuals afflicted with AIDS or a vaccine against AIDS which confers resistance to infection by AIDS associated retrovirus. The reverse transcriptase of an AIDS associated retrovirus is used separately or in a whole cell assay to identify compounds which selectively inhibit retroviral reverse transcriptase.

6657103, Dec 2, 2003

Sep 4, 1997

08/923138

Raju Kucherlapati - Darien CT
Aya Jakobovits - Menlo Park CA
Sue Klapholz - Stanford CA
Daniel G. Brenner - San Mateo CA
Daniel J. Capon - Hillsborough CA

Abgenix, Inc. - Fremont CA

C12P 2100

800 6, 800 4, 800 18, 4353201

Antibodies with fully human variable regions against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.

6673986, Jan 6, 2004

Mar 15, 1993

08/031801

Raju Kucherlapati - Darien CT
Aya Jakobovits - Menlo Park CA
Sue Klapholz - Stanford CA
Daniel G. Brenner - Redwood City CA
Daniel J. Capon - Hillsborough CA

Abgenix, Inc. - Fremont CA

A01K 67033

800 18, 800 13, 435325, 435455

The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci. Chimeric and transgenic mammals, particularly mice, are provided, having stably integrated large, xenogeneic DNA segments. The segments are introduced by fusion with yeast spheroplasts comprising yeast artificial chromosomes (YACs) which include the xenogeneic DNA segments and a selective marker such as HPRT, and embryonic stem cells.

6710169, Mar 23, 2004

May 28, 2002

10/157408

Daniel J. Capon - San Mateo CA
Timothy J. Gregory - Hillsborough CA

Genentech, Inc. - South San Francisco CA

C07K 14705

5303873, 530350, 536 234, 435 697

Novel derivatives of cell surface proteins which are homologous to the immunoglobulin superfamily (adhesons) are provided. Amino acid sequence variations are introduced into adheson, the most noteworthy of which are those in which the transmembrane and, preferably, cytoplasmic domains are rendered functionally inactive, and in which adheson extracellular domains replace an immunoglobulin variable region. These variants are useful in therapy or diagnostics, in particular, CD4 variants are therapeutically useful in the treatment of HIV infections.